NADPH Oxidases, Angiogenesis, and Peripheral Artery Disease

Pradeep Manuneedhi Cholan; Siân P Cartland; Mary M Kavurma

doi:10.3390/antiox6030056

NADPH Oxidases, Angiogenesis, and Peripheral Artery Disease

Antioxidants (Basel). 2017 Jul 12;6(3):56. doi: 10.3390/antiox6030056.

Authors

Pradeep Manuneedhi Cholan^{1

2}, Siân P Cartland^{3

4}, Mary M Kavurma^{5

6}

Affiliations

¹ Heart Research Institute, Sydney 2042, Australia. pradeep.cholan@hri.org.au.
² Sydney Medical School, the University of Sydney, Sydney 2006, Australia. pradeep.cholan@hri.org.au.
³ Heart Research Institute, Sydney 2042, Australia. sian.cartland@hri.org.au.
⁴ Sydney Medical School, the University of Sydney, Sydney 2006, Australia. sian.cartland@hri.org.au.
⁵ Heart Research Institute, Sydney 2042, Australia. mary.kavurma@hri.org.au.
⁶ Sydney Medical School, the University of Sydney, Sydney 2006, Australia. mary.kavurma@hri.org.au.

Abstract

Peripheral artery disease (PAD) is caused by narrowing of arteries in the limbs, normally occurring in the lower extremities, with severe cases resulting in amputation of the foot or leg. A potential approach for treatment is to stimulate the formation of new blood vessels to restore blood flow to limb tissues. This is a process called angiogenesis and involves the proliferation, migration, and differentiation of endothelial cells. Angiogenesis can be stimulated by reactive oxygen species (ROS), with NADPH oxidases (NOX) being a major source of ROS in endothelial cells. This review summarizes the recent evidence implicating NOX isoforms in their ability to regulate angiogenesis in vascular endothelial cells in vitro, and in PAD in vivo. Increasing our understanding of the involvement of the NOX isoforms in promoting therapeutic angiogenesis may lead to new treatment options to slow or reverse PAD.

Keywords: NADPH oxidases (NOX); angiogenesis; endothelial cell (EC); peripheral artery disease (PAD).

Publication types

Review